A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
← catalyst calendarNCT06945406 · readout ≤ 133 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
124estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-16 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
Interventions
- Drug: LY4057996 SC
- Drug: LY4057996 IV
- Drug: Placebo SC
- Drug: Placebo IV
- Drug: Degludec SC
- Drug: Lispro SC
- Drug: Degludec IV
- Drug: Pre-study basal insulin SC
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
measured Baseline to Study Completion (Up to 47 Weeks)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed